UCB SA (OTCMKTS:UCBJF – Get Free Report)’s share price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $193.22 and traded as low as $180.00. UCB shares last traded at $180.00, with a volume of 3,061 shares traded.
UCB Stock Performance
The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The firm’s 50 day moving average price is $193.22 and its 200-day moving average price is $185.32.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
See Also
- Five stocks we like better than UCB
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- How to Protect Your Portfolio When Inflation Is Rising
- What Are Treasury Bonds?
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
